Trial Profile
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Chondrosarcoma
- Focus Therapeutic Use
- 11 Sep 2019 Primary endpoint has not been met. (Disease control at week 16)
- 11 Sep 2019 Results published in the Cancer
- 22 Mar 2018 Status changed from active, no longer recruiting to completed.